SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
South Korea’s leading biologics companies will invest hundreds of billions of won to building additional plants that would push the total amount of private investments for the biohealth industry to 10 trillion won by 2023.
Samsung Biologics will pour 1.7 trillion won into its new Plant 4 while Celltrion will invest 500 billion won to its Global Life Science Research Lab and Plant 3, all in Songdo, Incheon.
As its action plan for a more robust bio-industry ecosystem, the Government also pledged a 1.7 trillion won budget in 2021, up 30 percent from last year’s. The budget will prioritize pharmaceuticals, medical devices, and digital health care.
Biohealth players are building an ecosystem for biologics in Songdo, which now hosts 60 South Korean and international bio-related companies, employing around 7,000.
About 10 trillion won of investment is expected to be made in the city by some 40 health care and venture capital firms by 2023.
It would boost manufacturing capacity by 20 percent and employ an additional 9,300.
The government envisions the biologics workforce to grow to 47,000 by 2025 in a joint effort with the academe.
The regional bio clusters of Songdo, Wonju in Gangwon Province, Osong in North Chungcheong Province, and Daegu will increase collaboration.
The biologics industry is globally increasing 4 percent annually, higher than shipbuilders at 2.9 percent and car manufacturers at 1.5 percent.
